LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

Intellia Therapeutics Inc

Open

SectorGezondheidszorg

11.36 -4.46

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.31

Max

12.05

Belangrijke statistieken

By Trading Economics

Inkomsten

13M

-101M

Verkoop

-2.4M

14M

Winstmarge

-710.811

Werknemers

403

EBITDA

11M

-108M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+149.66% upside

Dividenden

By Dow Jones

Volgende Winsten

6 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-37M

1.2B

Vorige openingsprijs

15.82

Vorige sluitingsprijs

11.36

Nieuwssentiment

By Acuity

54%

46%

320 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Intellia Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 apr 2025, 09:30 UTC

Top Nieuws

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

12 sep 2024, 17:01 UTC

Top Nieuws

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 sep 2024, 11:00 UTC

Top Nieuws

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Peer Vergelijking

Prijswijziging

Intellia Therapeutics Inc Prognose

Koersdoel

By TipRanks

149.66% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.56 USD  149.66%

Hoogste 60 USD

Laagste 7 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Intellia Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

16

Buy

3

Hold

0

Sell

Technische score

By Trading Central

7.24 / 8.43Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

320 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat